Center of Drug Discovery

Release date:2016-05-25  Release:

Center of Drug Discovery, College of Pharmaceutical Research, China Pharmaceutical University, is mainly focused on medicinal chemistry, drug discovery and new drug release system. In 2014, based on this center, “Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease” was established. The center now has 12 full professors, 2 associate professors, 3 lecturers, including 1 academician of the ChineseEngineering Academy, 1 “Yangtse River Scholar” awarded by Ministry of Education of the People’s Republic of China, 1 National Thousands of people plan young talent, 4 "New Century Excellent Talents" awarded by Ministry of Education of the People’s Republic of China, 2 "333 high-level personnel training project"at the second levelawarded by Jiangsu Province, 3 winners of China Pharmaceutical Association-SERVIER Youth Medicinal Chemist Award, 1 winner of national excellent doctoral dissertation nomination.

The laboratories of Center of Drug Discovery are mainly located in the Xuanwu district building, covering a total area of more than one thousand square meters, including chemical synthesis labs, analysis instrument lab, molecular biology lab, cell lab and center conference room, etc. The center has a number of advanced scientific instruments, such as peptide synthesizer, HPLC, GS-MS, IR, Optical tester, ELIASA, Q-PCR, etc. In recent five years, the center has obtained 20 National Natural Science Foundation of China, 7 National Science and Technology major projects, and signed more than 22 billion yuan new drug technology transfer contracts. In recent five years, the center has published more than 500 papers, including more than 300 SCI papers, including papers published at journalssuch asAngew.Chem.Int. Ed.(2)Adv. Mater. (1)J. Am. Chem. Soc. (2) and J. Med. Chem. (14),etc. 1.1 class of new drugs developed in the center include the antithrombotic drug“Vicagrel” (in phase I clinical trial), hypoglycemic drug “coumaglutide”(in preclinical studies), hypoglycemic drug “G004” (in preclinical studies), the novel lipid-lowering agent “oleanolic acid” (the early concept-proof clinical trial finished).

The main research fields of this center include: (1) drug discovery for metabolic diseases, cancer, and cardiovascular diseases;(2)new type of medicinal polymer materials and targeted drug release system; (3)studies on novel synthetic methodologies.

 

Director: SUN, HONGBIN

Secretary: ZHANG, WENJIE

  

Members:

PENG, SIXUN;

HUANG,WENLONG;

ZHANG, CAN;

ZHANG, HUIBIN;

LAI, YISHENG;

ZHANG, DAYONG;

QIAN, HAI;

MO, RAN;

LIU, XIAOXUAN;

WEN, XIAOAN;

HUANG, ZHANGJIAN;

XU, QINGLONG;

JU, CAOYUN;

XUE, LINGJING;

CHEN, CAIPING;

YUAN, HAOLIANG;

CHEN, HUACHAO;